Spironolactone side effects in women are one of the most-searched questions in dermatology and PCOS care, and for good reason: roughly 1 in 3 women prescribed it for acne or hirsutism reaches a daily dose where mild side effects become noticeable. This guide compiles current peer-reviewed evidence on what to expect — by frequency, by severity, and by who is most at risk — including how often serious electrolyte changes actually occur, which drug combinations matter, and what monitoring guidance current dermatology and gynecology bodies suggest. It is editorial information, not medical advice; specific decisions belong with a clinician.
Key facts at a glance
- Spironolactone is used off-label in women at 50-200 mg/day for acne, hirsutism, and PCOS-related androgen excess.
- The most common spironolactone side effects in women are menstrual irregularity, breast tenderness, frequent urination, and orthostatic dizziness.
- Hyperkalemia in healthy women under 45 occurs at roughly 0.72%, similar to baseline population rates¹.
- Pregnancy is the headline contraindication; reliable contraception is typically paired with therapy.
What spironolactone does and why side effects show up
Spironolactone is FDA-approved as a potassium-sparing diuretic for heart failure, hypertension, and edema, but the majority of women receiving it today take it off-label for androgen-driven skin and hair concerns⁴. At dermatologic doses (commonly 50-200 mg/day), it works in two ways: it blocks the mineralocorticoid receptor (the diuretic mechanism), and it competitively blocks the androgen receptor and reduces testosterone production. That dual mechanism explains the side-effect pattern. The mineralocorticoid action is responsible for increased urination, mild blood-pressure drops, and rare potassium retention. The anti-androgen action is responsible for menstrual changes, breast tenderness, and the pregnancy warning⁴.
A 2017 hybrid systematic review of oral spironolactone for adult female acne, covering studies from 1968 to 2016, concluded that side effects are typically mild, dose-dependent, and reversible, with discontinuation rates of 6-15% in most cohorts². Larger, longer-term datasets — including a 403-patient case series in JAAD covering up to 8 years of use — showed similar tolerability, with menstrual irregularity (21.9%), breast tenderness (5.2%), and orthostatic dizziness as the leading reasons women adjusted dose or stopped³.
Common spironolactone side effects in women: frequency by dose
Most studies group side effects by dose band (≤100 mg/day versus 100-200 mg/day). The pattern is consistent: side effects scale with dose.
Menstrual irregularities
Menstrual changes are the single most reported side effect. Across the 2017 Layton systematic review and the 2021 Garg case series, irregular bleeding, spotting, or amenorrhea were reported in roughly 15-30% of women on 100 mg/day and higher²ʼ³. Combining spironolactone with a combined oral contraceptive substantially reduces this rate. Importantly, menstrual changes do not appear to reflect ovarian harm; they reflect the drug's androgen-receptor blockade altering the cycle.
Breast tenderness and breast enlargement
Breast tenderness is reported by 5-26% of women in published series, again dose-dependent². Rates above 15% are typically seen only above 100 mg/day. True breast enlargement is less common and tends to occur at higher doses or with longer durations.
Diuretic-related effects
Because spironolactone is, mechanistically, a mild diuretic, the most universally reported side effect on starting therapy is increased urination — typically the first 2-4 weeks. Orthostatic dizziness (lightheadedness on standing) is reported by 5-10% of women and tends to resolve as the body adjusts²ʼ³. Drinking adequate water and avoiding rapid posture changes in the first weeks is a common clinical suggestion.
Headache, fatigue, and mood
Headache is reported in roughly 6-10% of women; fatigue in about 5-9%. Mood changes — low mood, irritability — are less consistently reported across the literature but appear in some long-term series at low single-digit rates³. Persistent mood symptoms are typically a reason to reassess therapy with a clinician.
Serious risks: hyperkalemia, blood pressure, and the pregnancy warning
The two risks that drive most clinical caution are hyperkalemia and pregnancy exposure.
The 2015 Plovanich JAMA Dermatology study of 974 healthy women under 45 taking spironolactone for acne measured 1,802 potassium levels and found a hyperkalemia rate of 0.72%, statistically equivalent to the baseline population rate of about 0.76% in this demographic¹. The authors concluded routine potassium monitoring in healthy young women without renal disease was low-yield. By contrast, in women over 65, on ACE inhibitors or ARBs, with chronic kidney disease, or on NSAIDs or potassium-sparing supplements, hyperkalemia risk rises meaningfully, and baseline and follow-up potassium and creatinine checks are commonly recommended⁴.
Blood pressure can drop modestly — typically 2-5 mmHg — at dermatologic doses. Women already on antihypertensives, or those with a history of orthostatic hypotension, generally have closer monitoring discussed with their prescriber.
The pregnancy warning is firm. Spironolactone crosses the placenta and theoretically can feminize a male fetus due to its anti-androgen effect, so the FDA labeling and ACOG-aligned PCOS guidance recommend avoiding pregnancy during treatment and pairing therapy with reliable contraception⁴ʼ⁸.
Treatment context: how clinicians weigh spironolactone alongside alternatives
Spironolactone is one of several options for androgen-driven concerns. In editorial summary form, common approaches discussed with patients include:
- Combined oral contraceptives (typically ethinyl estradiol + a low-androgenic progestin such as drospirenone or norgestimate), which both reduce ovarian androgen production and provide contraception.
- Spironolactone at 50-200 mg/day, often combined with a contraceptive for menstrual stability.
- Topical therapies for acne (retinoids, benzoyl peroxide, clascoterone 1% — the first topical anti-androgen, FDA-approved 2020).
- Metformin for PCOS where insulin resistance is dominant, per the 2023 International PCOS Guideline⁵.
- Inositol supplements, with growing but heterogeneous evidence for PCOS metabolic and androgenic markers⁵.
- Lifestyle and hair-specific options (electrolysis, laser hair reduction) for hirsutism.
Choice depends on goals (contraception vs. fertility-preserving), symptom dominance (skin vs. cycle vs. metabolic), and tolerance of side effects. These trade-offs are typically a conversation between a patient and a clinician with experience in PCOS or women's dermatology⁵ʼ⁸.
Telehealth options for women considering spironolactone
Several telehealth providers offer evaluations that can include spironolactone where clinically appropriate. They differ meaningfully in scope and pricing model, and brand mentions below link to our editorial reviews.
Allara is a multidisciplinary PCOS-focused telehealth practice that pairs clinicians with dietitians and accepts several commercial insurance plans, useful for patients who want PCOS-specific workups including androgen panels and metabolic labs.
Felix Health PCOS focuses on PCOS care with an async-friendly intake and lab ordering, and is often a fit for patients who want a single-condition focused experience without a broader women's-health subscription.
Midi Health is built around NAMS-certified clinicians and treats both perimenopausal symptoms and androgen-driven concerns; it accepts most commercial insurance plans, which can shift the out-of-pocket cost calculation versus cash-pay options.
Hers Weight Loss and its broader Hers women's health platform offer dermatology consults for acne where spironolactone may be considered alongside topical therapies, on a cash-pay subscription model.
Some brand mentions in this article link to our editorial reviews; we do not rank these providers as "best" because the right fit depends on insurance, condition specifics, and clinician preference.
Safety: when to flag symptoms and who should generally avoid spironolactone
Per FDA labeling and current dermatology and gynecology guidance, spironolactone is generally avoided or used with extra caution in:
- Pregnancy or active attempts to conceive⁴
- Significant chronic kidney disease (eGFR <30 mL/min/1.73m²)
- Baseline hyperkalemia (potassium >5.0 mmol/L)
- Addison's disease or other adrenal insufficiency
- Concurrent use of potassium supplements, ACE inhibitors, ARBs, or potassium-sparing diuretics without monitoring⁴
Symptoms that typically warrant prompt clinical contact include irregular or very slow heartbeat, severe muscle weakness, numbness or tingling, fainting, severe headaches, signs of dehydration, or any symptom suggesting an allergic reaction. Persistent breast lumps, abnormal vaginal bleeding patterns lasting beyond 3 months, or new mood changes are also commonly listed as reasons to reassess therapy⁴.
Cost and insurance considerations
Generic spironolactone is widely available and inexpensive. Typical U.S. retail cash prices for 50 mg or 100 mg tablets run roughly $10-$30 for a 30-day supply, and discount programs frequently bring it under $15⁴. Most commercial insurance plans cover spironolactone with a low generic tier copay; Medicare Part D coverage is similarly broad. The larger cost variable is usually the visit pathway, not the drug itself: in-person dermatology and gynecology visits, lab work for potassium and creatinine where indicated, and telehealth subscription fees (commonly $25-$80/month for women's health platforms, with insurance models charging only a copay) make up the bulk of out-of-pocket spend. Coverage of telehealth visits varies by plan and state, and specific verification is typically done at intake.
Frequently asked questions
What are the most common spironolactone side effects in women? The most frequent spironolactone side effects in women are menstrual irregularity, breast tenderness, increased urination, mild dizziness on standing, and headache. Most are dose-dependent and tend to settle within 1-3 months. Severe reactions such as hyperkalemia are uncommon in healthy women under 45.
Does spironolactone cause weight gain or weight loss in women? Spironolactone is a potassium-sparing diuretic, so most women experience a small initial loss of water weight rather than fat. Long-term weight gain is not a well-documented effect in randomized trials. Any persistent weight change should be discussed with a prescribing clinician.
How long do spironolactone side effects last? Most acute side effects — dizziness, frequent urination, breast tenderness, menstrual changes — appear within the first 4-12 weeks and often improve as the body adjusts. Side effects that persist beyond 3 months, or that worsen, are typically a signal to revisit dose or therapy choice with a clinician.
Can spironolactone affect fertility or pregnancy? Spironolactone is labeled pregnancy category C and is generally avoided when trying to conceive because of theoretical feminization risk to a male fetus. It does not appear to permanently impair fertility, but reliable contraception is usually discussed alongside prescriptions for acne, hirsutism, or PCOS.
Do I need blood tests while taking spironolactone? Guidelines vary. For healthy women under 45 without kidney disease, routine potassium monitoring is often considered low-yield based on Plovanich et al. 2015. Higher-risk patients — older adults, those on ACE inhibitors, ARBs, or NSAIDs, or with renal impairment — typically have baseline and follow-up potassium and creatinine checks.
What drugs interact with spironolactone? Spironolactone interacts with ACE inhibitors, ARBs, NSAIDs, potassium supplements, certain antibiotics (trimethoprim), and lithium, all of which can raise potassium or alter drug levels. A full medication and supplement list should be reviewed with a prescribing clinician before starting.
Sources
- Plovanich M, Weng QY, Mostaghimi A. Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatol. 2015;151(9):941-944. https://pubmed.ncbi.nlm.nih.gov/25796182/
- Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, et al. Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review. Am J Clin Dermatol. 2017;18(2):169-191. https://pubmed.ncbi.nlm.nih.gov/28155090/
- Garg V, Choi JK, James WD, Barbieri JS. Long-term use of spironolactone for acne in women: a case series of 403 patients. J Am Acad Dermatol. 2021;84(5):1348-1355. https://pubmed.ncbi.nlm.nih.gov/33307146/
- U.S. Food and Drug Administration. Aldactone (spironolactone) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012151s075lbl.pdf
- Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril. 2023;120(4):767-793. https://pubmed.ncbi.nlm.nih.gov/37589624/
- Roberts EE, Nowsheen S, Davis MDP, et al. Use of spironolactone to treat acne in adolescent females. Pediatr Dermatol. 2021;38(1):72-76. https://pubmed.ncbi.nlm.nih.gov/33247448/
- Charny JW, Choi JK, James WD. Spironolactone for the treatment of acne in women, a retrospective study of 110 patients. Int J Womens Dermatol. 2017;3(2):111-115. https://pubmed.ncbi.nlm.nih.gov/28560306/
- ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstet Gynecol. 2018;131(6):e157-e171. https://pubmed.ncbi.nlm.nih.gov/29794677/
Related brands & guides
- Allara — multidisciplinary PCOS telehealth
- Felix Health PCOS
- Midi Health — NAMS-certified women's clinicians
- Hers Weight Loss & Women's Health
Updated 2026-05-29. Reviewed by Dr. Maya Chen, MD, NAMS-CMP. Some brand mentions in this article link to our editorial reviews. This article is editorial information, not medical advice; treatment decisions belong with a qualified clinician.